Clinical Trial Update: Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating chidamide in combination with angiogenesis inhibitors and fulvestrant for advanced HR-positive, HER2-negative breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Angiogenesis inhibitors
• Chidamide (chidamide)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Jundong Wu | Conditions: Advanced Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING